These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23250964)

  • 1. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
    Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
    Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy: A Single-Site Retrospective Longitudinal Study.
    Trucco F; Domingos JP; Tay CG; Ridout D; Maresh K; Munot P; Sarkozy A; Robb S; Quinlivan R; Riley M; Burch M; Fenton M; Wallis C; Chan E; Abel F; Manzur AY; Muntoni F
    Chest; 2020 Oct; 158(4):1606-1616. PubMed ID: 32387519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
    McDonald CM; Henricson EK; Abresch RT; Duong T; Joyce NC; Hu F; Clemens PR; Hoffman EP; Cnaan A; Gordish-Dressman H;
    Lancet; 2018 Feb; 391(10119):451-461. PubMed ID: 29174484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
    Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth pattern trajectories in boys with Duchenne muscular dystrophy.
    Stimpson G; Raquq S; Chesshyre M; Fewtrell M; Ridout D; Sarkozy A; Manzur A; Ayyar Gupta V; De Amicis R; Muntoni F; Baranello G;
    Orphanet J Rare Dis; 2022 Jan; 17(1):20. PubMed ID: 35073949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying Variability in Motor Function in Duchenne Muscular Dystrophy: UK Centiles for the NorthStar Ambulatory Assessment, 10 m Walk Run Velocity and Rise from Floor Velocity in GC Treated Boys.
    Stimpson G; Ridout D; Wolfe A; Milev E; O'Reilly E; Manzur A; Sarkozy A; Muntoni F; Cole TJ; Baranello G;
    J Neuromuscul Dis; 2024; 11(1):153-166. PubMed ID: 37980680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prednisolone treatment for Duchenne muscular dystrophy].
    Shimomura H; Fujii T; Miyajima T; Kumada T; Kimura N; Oda N; Saito K
    No To Hattatsu; 2011 Jan; 43(1):24-9. PubMed ID: 21400928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.
    Ricotti V; Ridout DA; Pane M; Main M; Mayhew A; Mercuri E; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):149-55. PubMed ID: 25733532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.
    Bello L; Gordish-Dressman H; Morgenroth LP; Henricson EK; Duong T; Hoffman EP; Cnaan A; McDonald CM;
    Neurology; 2015 Sep; 85(12):1048-55. PubMed ID: 26311750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in steroid therapy for Duchenne muscular dystrophy in Japan.
    Takeuchi F; Komaki H; Nakamura H; Yonemoto N; Kashiwabara K; Kimura E; Takeda S
    Muscle Nerve; 2016 Oct; 54(4):673-80. PubMed ID: 26910583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.